The funding will support the clinical progression and regulatory advancement of the company proprietary nanoclay platform.
"advancing the development of [their] orthobiologics product, RENOVITE® nanoclay, and progressing through regulatory milestones to get this technology closer to clinic and spinal fusion patients."
The pre-seed round was led by Speedinvest to support the rollout of the company protocol in December.
"Interest Rate Derivatives represent the largest asset class in traditional finance with over $500T in outstanding interest. Our ultimate goal is to introduce this market to the advantages of on-chain trading while offering crypto traders the opportunity to trade the most prominent rates in the ecosystem, as enjoyed by participants of TradFi markets."
The investment was led by Maven Capital Partners to fund international growth and product expansion.
"Sensoteq has developed and launched a market-leading product, giving clients access to previously unobtainable data that is invaluable in ensuring the health and ongoing performance of key production equipment. We have been hugely impressed by the global reach of the company and demand for the technology, and we are aware that customers greatly value and rely upon the technical expertise and support of the entire Sensoteq team. We look forward to working with Idir and Alan to further grow the business."